- Announced that Mr. Derek Theriault has been hired as National Sales Director and Michael Olders has been hired as Director Operations and Logistics.
Derek Theriault, National Sales Director
Michael Olders, Director Operations and Logistics
ORLEANS, Ontario, Jan. 14, 2019 — Tetra Natural Health, a subsidiary of Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF), is pleased to announce that Mr. Derek Theriault has been hired as National Sales Director and Michael Olders has been hired as Director Operations and Logistics.
Derek Theriault, National Sales Director – has 20
years’ experience within the pharmaceutical industry and has held
various sales and leadership roles during this time. He was pivotal to
the launch of several companies including the development of their sales
forces and penetration of the Canadian market. Derek has a proven track
record for strategically building market-share for several brand name
medications, over-the-counter (OTC) drugs and natural products. Derek is
recognized for his ability to lead sales teams as well as to help grow
the talent base within the organization while reaching and surpassing
the milestones that were set forth. He is also known for his passion for
coaching, his strong ethical standards and his ability to respond to
seize opportunities.
Michael Olders, Director Operations and Logistics
– With more than two decades of experience, Michael has held several
leadership positions in Operations and Logistics in a variety of
industries. Having worked for small privately-owned businesses as well
as large multinational corporations, he is known for finding ways to
increase efficiencies while lowering costs, often using technology to
achieve significant positive results. Teamwork, communication and
integrity are hallmarks of Michael’s approach to growing business and
profits and exceeding goals. He studied at Selwyn House School, Collège
Brébeuf and McGill University, and is passionate about continuous
learning, technology, his family and the Montreal Canadiens.
“I am very proud to add Derek Theriault and Michael Olders to the
Tetra Natural Health management team. Their combined solid experience
and track records with OTC drugs and natural health products will enable
us to grow our portfolio of products and our commercial results
significantly over the coming year and contribute to the consolidated
results of Tetra Bio-Pharma,†says Richard Giguere, Chief Executive
Officer of Tetra Natural Health.
About Tetra Natural Health:
Tetra Natural Health
inc. is a subsidiary of Tetra Bio-Pharma inc. that focuses on
identification, development and marketing of hemp or cannabis-based
natural health products, or cannabinoids-based products authorized for
sale by Health Canada.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved and FDA reviewed clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Tetra Bio-Pharma has subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of its mission, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. For more information visit: www.tetrabiopharma.com
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this
release.
Forward-looking statements
Some statements in
this release may contain forward-looking information. All statements,
other than of historical fact, that address activities, events or
developments that the Company believes, expects or anticipates will or
may occur in the future (including, without limitation, statements
regarding potential acquisitions and financings) are forward-looking
statements. Forward-looking statements are generally identifiable by use
of the words “may”, “will”, “should”, “continue”, “expect”,
“anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or
the negative of these words or other variations on these words or
comparable terminology. Forward-looking statements are subject to a
number of risks and uncertainties, many of which are beyond the
Company’s ability to control or predict, that may cause the actual
results of the Company to differ materially from those discussed in the
forward-looking statements. Factors that could cause actual results or
events to differ materially from current expectations include, among
other things, without limitation, the inability of the Company to obtain
sufficient financing to execute the Company’s business plan;
competition; regulation and anticipated and unanticipated costs and
delays, the success of the Company’s research and development
strategies, the applicability of the discoveries made therein, the
successful and timely completion and uncertainties related to the
regulatory process, the timing of clinical trials, the timing and
outcomes of regulatory or intellectual property decisions and other
risks disclosed in the Company’s public disclosure record on file with
the relevant securities regulatory authorities. Although the Company has
attempted to identify important factors that could cause actual results
or events to differ materially from those described in forward-looking
statements, there may be other factors that cause results or events not
to be as anticipated, estimated or intended. Readers should not place
undue reliance on forward-looking statements. While no definitive
documentation has yet been signed by the parties and there is no
certainty that such documentation will be signed The forward-looking
statements included in this news release are made as of the date of this
news release and the Company does not undertake an obligation to
publicly update such forward-looking statements to reflect new
information, subsequent events or otherwise unless required by
applicable securities legislation.
More information at: www.tetrabiopharma.com
For further information, please contact:
Richard Giguère
Chief Executive Officer
Tetra Natural Health
[email protected]
For investors information, please contact:
[email protected]
(438) 504-5784
Media Contact:
Daniel Granger, C.M.
ACJ Communication
T. 514 840-7990
M. 514 232 1556
[email protected]
Charlotte Blanche
T. 514 840-1235 ext. 7772
M. 514 914-0593
[email protected]
Two photos accompanying this announcement are available at:
http://www.globenewswire.com/NewsRoom/AttachmentNg/7d0b2157-04d4-4cf9-9c4e-1321278ae8d5http://www.globenewswire.com/NewsRoom/AttachmentNg/6d9ea9f6-9ca3-4f8d-b8f1-ffbf17bff3d6
